KDventures' Umecrine Cognition survey finds severe fatigue in 44% of PBC patients

• KDventures announced that portfolio company Umecrine Cognition’s patient survey received Poster of Distinction recognition at The Liver Meeting 2026.
• Findings will be presented in Denver in November 2026, highlighting severe fatigue’s impact on daily functioning despite standard treatment for primary biliary cholangitis.
• Severe fatigue was associated with worse quality of life, reinforcing the need for treatments targeting fatigue and cognitive symptoms.
• Umecrine Cognition is developing golexanolone for these symptoms; the first part of its Phase 1b/2a study found it safe and well tolerated.
• Topline study results are expected in November 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.